Turbine Announces Collaboration to Uncover Biological Mechanisms of Drug Resistance in Hematological Cancers
Turbine (AZN): Turbine, a leading biological simulation company, collaborates with AstraZeneca to identify resistance mechanisms in hematological cancers using its Simulated Cell™ platform.
The collaboration between Turbine and AstraZeneca represents a significant step in the application of computational methods to understand and combat hematological cancers. Turbine's Simulated Cell™ platform employs advanced algorithms and machine learning to simulate how cancer cells operate and respond to treatments. This partnership could potentially lead to groundbreaking discoveries in identifying resistance mechanisms to therapy, a major challenge in cancer treatment.
From a biotechnology perspective, the application of in silico platforms like Turbine's can drastically reduce the time and cost associated with drug discovery and development. It enables researchers to conduct virtual experiments and predict outcomes with a high degree of accuracy. For AstraZeneca, leveraging such technology may accelerate their R&D efforts and lead to more efficient pathways in bringing personalized therapies to the market.
While financial terms were not disclosed, the success of this collaboration could translate into substantial economic value for both entities. For the broader industry, it sets a precedent for the integration of computational biology in drug development processes, potentially reshaping the landscape of personalized medicine and its commercial viability.
The strategic partnership between Turbine and AstraZeneca underscores the growing importance of personalized medicine in the healthcare industry. Understanding protein-protein interactions and their role in therapy resistance is crucial for the development of targeted treatment regimens. Personalized treatments can lead to improved patient outcomes and may reduce healthcare costs by minimizing ineffective treatments.
For stakeholders, the short-term implications may include fluctuations in AstraZeneca's stock price as the market reacts to the potential of this collaboration. Long-term benefits, however, hinge on the successful identification of resistance mechanisms and the subsequent development of effective therapies. If successful, AstraZeneca could strengthen its position in the oncology market, a field that is highly competitive and rapidly evolving.
It is also worth noting that collaborations like this can influence regulatory policies and insurance coverage as new therapies emerge. The success of such partnerships will likely encourage further investment in precision medicine, which could lead to a shift in how treatment protocols are developed and approved.
The undisclosed financial terms of the Turbine-AstraZeneca collaboration might raise questions among investors regarding the potential return on investment. However, the strategic nature of this partnership could indicate a significant commitment from AstraZeneca to bolster its pipeline in oncology, a sector that is crucial for its growth. The focus on hematological cancers, which include various forms of leukemia and lymphoma, taps into a market with a strong demand for innovative treatments.
Investors should consider the implications of this collaboration on AstraZeneca's long-term growth trajectory. The integration of Turbine's Simulated Cell™ platform into AstraZeneca's R&D could lead to a competitive edge in personalized oncology treatments, a market that is expected to grow substantially. Additionally, the success of this collaboration could serve as a catalyst for further strategic partnerships, potentially enhancing AstraZeneca's market share and investor confidence.
The biotechnology sector is known for its high risk-reward ratio and collaborations that marry cutting-edge technology with a robust drug development pipeline are particularly attractive. Investors will be watching closely for any progress updates, as these could have a material impact on AstraZeneca's valuation and the stock market's perception of the company's innovation capabilities.
01/05/2024 - 03:00 AM
LONDON & BUDAPEST, Hungary --(BUSINESS WIRE)--
Turbine, a leading biological simulation company building a platform for interpreting human biology in silico , today announced it has entered into a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical company. Turbine will use its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers. The collaboration will focus on understanding resistance mechanisms resulting from altered protein-protein interactions, which could enable more personalized treatment regimens based on each patient’s molecular profile. Financial terms of the collaboration are not disclosed.
“Over the past several years, Turbine has been working with researchers at AstraZeneca to evaluate our platform’s ability to identify mechanisms and potential biomarkers of response or resistance to personalized treatment combinations,” said Szabolcs Nagy, Chief Executive Officer and Co-Founder of Turbine. “The collaboration announced today builds on the promise our platform has shown and will see us apply this technology to answer new questions about molecular alterations that give rise to drug resistance and how they could be overcome. We’re excited about the opportunity to expand our collaboration with AstraZeneca with the aim of supporting the development of better, more durable therapies for the patients who need them.”
Turbine and AstraZeneca previously collaborated using an earlier version of the Simulated Cell to predict combination synergy and relevant biomarker candidates involving DNA Damage Repair mechanisms. In this study, the team evaluated hundreds of drug combinations in multiple cancers and demonstrated that the platform is capable of predicting their effect, without training on the experimental data itself. Simulations were used to identify potential mechanisms underlying the synergy between combinations of cancer treatments, revealing biomarkers of response and resistance that could be translated into clinical practice. The results of these studies, which demonstrated that Turbine’s platform matches the predictivity while adding deeper insights into the biological complexity of response mechanisms, have been posted to the bioRxiv
About Turbine
Based in London with offices in Budapest, Hungary and Cambridge, UK , Turbine was founded in 2016 by Kristof Szalay Ph.D., Daniel Veres, M.D., Ph.D., Szabolcs Nagy and Ivan Fekete, M.D. The team’s vision is to overcome the limitations in developing oncology treatments with true patient benefit by building the world’s first predictive simulation of human biology through combining machine learning and molecular biology.
Turbine’s Simulated Cell™ is an interpretable cell simulation platform that captures patient biology better than currently available models, and is used for in silico experiments at scales impossible in physical assays. From billions of simulated experiments, the team uncovers novel hypotheses and the mechanisms underlying them. Simulations are validated in Turbine’s state-of-the-art laboratory facility and the resulting data is fed back to train an ever expanding and more predictive simulation of human biology. The Simulated Cells can be integrated into all steps of biopharma R&D to boost its likelihood of success, from identifying novel targets invisible to high throughput biological screening to optimally targeting existing therapies at the most responsive patients.
Simulations have already been validated from target discovery to patient stratification and life cycle management through Turbine’s proprietary pipeline and collaborations with multiple big pharma companies and research institutions, including Bayer, Ono Pharmaceutical and Cancer Research Horizons. Turbine’s latest investment round (Series A) was closed in 2022 and co-led by MSD (Merck & Co., Inc., Rahway NJ , USA) Global Health Innovation Fund, MassMutual Ventures and Mercia Asset Management, who were joined by existing investors Accel, Delin Ventures, and XTX Ventures.
For more information, visit www.turbine.ai or follow Turbine on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240105425138/en/
Corporate Inquiries:
balint.paholcsek@turbine.ai
Media Inquiries:
hal@torchcomllc.com
Source: Turbine
Turbine has entered into a collaboration with AstraZeneca to identify and understand mechanisms of resistance to therapy in hematological cancers using its Simulated Cell™ platform.
Turbine will use its proprietary Simulated Cell™ platform to identify mechanisms of resistance to therapy in hematological cancers.
Szabolcs Nagy is the Chief Executive Officer and Co-Founder of Turbine.
The collaboration will focus on understanding resistance mechanisms resulting from altered protein-protein interactions in hematological cancers.
No, financial terms of the collaboration are not disclosed.
